Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease

BACKGROUND: Fabry disease (FD) is a progressive multisystemic disease characterized by a lysosomal enzyme deficiency. A lack of α-galactosidase A (α-Gal A) activity results in the progressive systemic accumulation of its substrates, including globotriaosylceramide (Gb3) and globotriaosylsphingosine...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Mulan, Zhou, Hongyu, He, Shaomei, Qiu, Haoheng, Wang, Yanping, Zhao, April Yuanyi, Mu, Yunping, Li, Fanghong, Zhao, Allan Zijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481556/
https://www.ncbi.nlm.nih.gov/pubmed/37670350
http://dx.doi.org/10.1186/s13023-023-02894-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481556/
https://www.ncbi.nlm.nih.gov/pubmed/37670350
http://dx.doi.org/10.1186/s13023-023-02894-0

Ejemplares similares